4 Einträge gefunden

1. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

   1. Richardson, Paul G
   2. Schjesvold, Fredrik
   3. Weisel, Katja
   4. Moreau, Philippe
   5. Anderson, Larry D
   6. White, Darrell
   7. Rodriguez-Otero, Paula

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

   1. Dimopoulos, Meletios
   2. Weisel, Katja
   3. Moreau, Philippe
   4. Anderson, Larry D
   5. White, Darrell
   6. San-Miguel, Jesus
   7. Sonneveld, Pieter

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

   1. Dimopoulos, Meletios A
   2. Lonial, Sagar
   3. White, Darrell
   4. Moreau, Philippe
   5. Weisel, Katja
   6. San-Miguel, Jesus
   7. Shpilberg, Ofer

   2020 - Forschungsinformationssystem des UKE
4. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

   1. Richardson, Paul G
   2. Oriol, Albert
   3. Beksac, Meral
   4. Liberati, Anna Marina
   5. Galli, Monica
   6. Schjesvold, Fredrik
   7. Lindsay, Jindriska

   2019 - Forschungsinformationssystem des UKE